rated a higher risk because of both its unique and unproven bolt-together design, and because it had no governmental past performance record. In addition, IMG had no experience with armored vehicles and depended on a foreign supplier as its source of armor. Based on the source selection analysis and because the urgent nature of the program demanded many vehicles, the PM awarded IDIQ contracts to nine of the ten competing manufacturers, including even high-risk manufacturers such as IMG. The IDIQ contracts included immediate production orders for a minimum number of prototype vehicles for testing. Only one manufacturer was eliminated at this point based on the committee’s determination that it had no chance of successfully contributing to the program.
The second component of source selection consisted of the first phase of developmental testing, known as DT-C1. Focused heavily on survivability—with a minimum level of user, safety, and automotive testing—this phase served as a screening
process for the first round deliver test vehicles, two and two more failed to
of large LRIP orders. Of the nine manufacturers on contract to failed to provide the vehicles within the 60-day requirement,
manufacturer, OTC, was eliminated from the IMG passed and, following further testing,
program in this phase went on to become
of testing, whereas the largest MRAP
producer. Of the five manufacturers that were awarded large LRIP orders. This
successfully passed the DT-C1 requirements, source selection approach allowed the JPO
quickly identify suitable vehicles, get them into production, production orders to certain manufacturers once future phases inform the source selection.
The decision to maximize participation and the associated competition was arguably costly; however, it improved the end product by bringing innovation to the program. IMG, which was initially deemed a high-risk manufacturer, brought both an innovative design and a manufacturing capability unequalled in the program, providing the best example of a successful and rapid expansion of the industrial base in support of the requirement. OTC failure in the first phase of testing and subsequent removal from